{"id":290682,"date":"2019-11-07T14:59:07","date_gmt":"2019-11-07T19:59:07","guid":{"rendered":"https:\/\/news.harvard.edu\/gazette\/?p=290682"},"modified":"2023-11-08T20:28:42","modified_gmt":"2023-11-09T01:28:42","slug":"radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits","status":"publish","type":"post","link":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/","title":{"rendered":"Brokering an opioid settlement"},"content":{"rendered":"<header\n\tclass=\"wp-block-harvard-gazette-article-header alignfull article-header is-style-full-width-text-below centered-image\"\n\tstyle=\" \"\n>\n\t<figure class=\"wp-block-image\"><img fetchpriority=\"high\" decoding=\"async\" alt=\"Pills laid out on a table.\" height=\"1667\" loading=\"eager\" src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\" width=\"2500\"\/><figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--credit\">Stephen Foster\/Unsplash<\/p><\/figcaption><\/figure>\n\n\t<div class=\"article-header__content\">\n\t\t\t<a\n\t\t\tclass=\"article-header__category\"\n\t\t\thref=\"https:\/\/news.harvard.edu\/gazette\/section\/nation-world\/\"\n\t\t>\n\t\t\tNation &amp; World\t\t<\/a>\n\t\t\n\t\t<h1 class=\"article-header__title wp-block-heading \">\n\t\tBrokering an opioid settlement\t<\/h1>\n\n\t\n\t\t\t<\/div>\n\t\t\n\t<div class=\"article-header__meta\">\n\t\t<div class=\"wp-block-post-author\">\n\t\t\t<address class=\"wp-block-post-author__content\">\n\t\t\t\t\t<p class=\"author wp-block-post-author__name\">\n\t\tColleen Walsh\t<\/p>\n\t\t\t<p class=\"wp-block-post-author__byline\">\n\t\t\tHarvard Staff Writer\t\t<\/p>\n\t\t\t\t\t<\/address>\n\t\t<\/div>\n\n\t\t<time class=\"article-header__date\" datetime=\"2019-11-07\">\n\t\t\tNovember 7, 2019\t\t<\/time>\n\n\t\t<span class=\"article-header__reading-time\">\n\t\t\t8 min read\t\t<\/span>\n\t<\/div>\n\n\t\n\t\t\t<h2 class=\"article-header__subheading wp-block-heading\">\n\t\t\tRadcliffe fellow discusses prospects for a sweeping agreement in lawsuits\t\t<\/h2>\n\t\t\n<\/header>\n\n\n\n<div class=\"wp-block-group alignwide has-global-padding is-content-justification-center is-layout-constrained wp-block-group-is-layout-constrained\">\n\n\n\t\t<p>Drug companies and distributors are facing thousands of lawsuits filed by U.S. cities, towns, and tribal governments whose communities have been ravaged by the opioid epidemic, which has claimed hundreds of thousands of lives from overdoses. Resolving all those legal actions separately is impractical, many legal experts say. Instead, lawyers for the states and attorneys general are exploring a solution that would resolve all the cases in a so-called \u201cglobal deal.\u201d Currently two drug companies and three distributors have proposed a settlement framework for such a deal worth approximately $48 billion that would include cash and medication to treat addiction. But many local governments are wary of such an arrangement, skeptical about how the money would be divided. The Gazette spoke with <a href=\"https:\/\/www.radcliffe.harvard.edu\/people\/alexandra-d-lahav\">Alexandra Lahav,<\/a> 2019-20 Matina S. Horner Distinguished Visiting Professor at Harvard\u2019s <a href=\"https:\/\/www.radcliffe.harvard.edu\/\">Radcliffe Institute for Advanced Study, <\/a>and professor at the University of Connecticut who studies tort law, about how global settlements operate.<\/p>\n<h2 class=\"wp-block-heading\">Q&amp;A<\/h2>\n<h3 class=\"wp-block-heading\">Alexandra Lahav<\/h3>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is a global settlement? Do all parties involved have to sign on or agree to it?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> A global settlement is an agreement that includes everyone involved in a large-scale litigation. An example is the class action. In a class action, all the people who meet a certain description \u2014 for example, cellphone customers during a certain period \u2014 are included in the class. They are represented by a named plaintiff, and if that lawsuit reaches a settlement they would all be bound by it and not be able to sue on their own. But there are other ways to reach a global settlement as well. For example, a defendant can offer a single amount in settlement on condition that everyone who has a claim against them agrees to be part of that settlement. What makes a settlement global is that everyone or nearly everyone agrees to sign on.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>Can you talk a bit about the discussions around crafting an agreement to settle the thousands of opioids lawsuits?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>Right now, several attorneys general have suggested a global settlement in the opioids litigation. In that case, there is a very novel settlement structure on the table. The court has certified a class action, which includes all the cities and towns in the United States. They have the option to opt out of this class. If they don\u2019t, then they are deemed to have agreed to the following structure: When a settlement is reached, the terms will be circulated to the class. If 75 percent approve of the settlement, it will bind everyone, even the 25 percent who did not approve. This is called a \u201cnegotiated class action,\u201d and it has never been tried before. It was the idea of a Harvard law professor, William Rubenstein, and a Duke law professor, Francis McGovern.<\/p>\n\r\n\t\n\n\t<figure class=\"wp-block-image alignright  size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1707\" height=\"2560\" src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg\" alt=\"Alexandra Lahav, Radcliffe fellow.\" class=\"wp-image-290705\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg 1707w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=100,150 100w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=200,300 200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=768,1152 768w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=683,1024 683w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=1024,1536 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=1366,2048 1366w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=21,32 21w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=43,64 43w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=1488,2232 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg?resize=1680,2520 1680w\" sizes=\"auto, (max-width: 1707px) 100vw, 1707px\" \/><figcaption class=\"wp-element-caption\">&quot;It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on,&quot; said Alexandra Lahav. Photo by Tony Rinaldo\t\t\t<\/figcaption><\/figure>\n\t\n\t\r\n\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is the challenge with this type of arrangement?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>There are a few. First, will everyone agree to join this settlement structure, knowing that they will be bound by a supermajority vote? Second, what about the attorneys general who have brought separate lawsuits, many of whom have opposed this settlement structure? Also what is the relationship between the state attorney general that represents the state as a whole, and all of the state\u2019s subdivisions? For example, let\u2019s say all the cities and towns in Massachusetts are included in a settlement. What then is the role of Attorney General Maura Healey? Is the whole greater than the sum of its parts? I haven\u2019t heard of anybody who knows the answer to this. It\u2019s sort of a local government question in a way. And each state law is going to be different with respect to the power of cities and towns to sue when the state is also suing.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What\u2019s the advantage of settling the lawsuits in this way?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>It\u2019s not realistic that every case is going to go to trial. We are talking about many thousands of cases, and the system just can\u2019t handle it. You can imagine a world where the judge holds a trial every six months, and the defendant settles one for $200 million here and another for $200 million there, and this goes on and on and on. That&#8217;s just not good for the communities, and it\u2019s not good for the defendants. The idea behind a global settlement is to come up with something that benefits both and that resolves the dispute.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> How would a global settlement like this compare to the Big Tobacco case in 1998?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> There are some similarities, in that both are public health crises that led to massive lawsuits. But there are also a few important differences. First, the tobacco cases were settled exclusively by state attorneys general. Here both attorneys general and individual municipalities are suing, and they have more competing interests. This makes it harder to reach a global agreement. Second, there appears to be less money available here than there was in the tobacco case, which settled for around $200 billion.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> Do you think public anger and the desire for an admission of guilt or an apology factor into whether or not these cases end in a settlement, or are taken to trial?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on. Others have played a relatively small role in the opioid crisis. That said, I do think people want accountability. But you know, one of the things about the American system that\u2019s so interesting is that we do settle a lot of cases, and in most of those settlements, there is no apology, and there is no admission of liability. Instead, we sort of take the amount of money as the apology and the admission of liability, as if the dollars speak for the accountability.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What can be put in place in these settlements to stop similar crises from happening?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> This is a very difficult question to answer. The general theory of deterrence says that if wrongdoers are forced to pay for the harms they cause, then in the future companies considering wrongdoing will not do similar things. We hope that is the case. But it isn\u2019t clear that a litigation can prevent the kind of regulatory failure that we saw in the opioids situation. If there is a settlement it\u2019s likely to provide some relief to states and localities that are suffering, but it is not clear what preventative effect it will have.<\/p>\n\r\n<div class=\"wp-block-harvard-gazette-supporting-content alignleft supporting-content\" id=\"supporting-content-11de4a1e-1353-4dd2-8ead-51f99878bad3\">\n\t<div class=\"featured-articles is-post-type-post is-style-grid-list\"  style=\"\">\n\t\t\t\t\t\t<h2 class=\"featured-articles__title wp-block-heading\">More like this<\/h2>\n\t\t\t\t<ul class=\"featured-articles__list \">\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"Raina McMahan and Dr. Sarah Wakeman at the confernce\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/10\/stigma-of-opioids-keeps-users-from-seeking-help-taints-views-of-medical-professionals\/\">Stigma of opioids a hurdle to solving crisis<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-10-11\">\n\t\t\t\t\t\t\tOctober 11, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t6 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"Pills spilling from a bottle\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/05\/harvard-michigan-opioid-summit-explores-addiction-policy\/\">Pharma-to-doc marketing a vulnerability in opioid fight<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-05-13\">\n\t\t\t\t\t\t\tMay 13, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t6 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"assortment of pills\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/03\/dramatic-shifts-in-first-time-opioid-prescriptions-bring-hope-concern\/\">First-time opioid prescriptions drop by 50 percent<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-03-13\">\n\t\t\t\t\t\t\tMarch 13, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t4 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"A fentanyl user holds a needle.\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2018\/12\/harvard-psychologist-discusses-decline-in-u-s-life-expectancy\/\">A nation nearer to the grave<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2018-12-10\">\n\t\t\t\t\t\t\tDecember 10, 2018\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\tlong read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\t\t<\/ul>\n\t\t\t<\/div>\n\n\t<\/div>\r\n\r\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What do you expect to happen next and what are the chances that the global settlement under consideration will be achieved?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Right now there is a settlement proposal on the table proposed by several attorneys general for $48 billion over a period of years. But it is not clear that it will be agreed to by the lawyers for the local governments, who at the moment are opposing it. And some states have also voiced concerns. In order to reach a global settlement, that proposal would need the agreement of the lawyers representing this class of localities. I think we will see a settlement eventually, but when and for how much remains to be seen.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Are there specific reasons why plaintiffs like or prefer a global settlement, and why defendants prefer it?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Defendants prefer a global settlement because they can wrap up their liability at once. This allows them to announce to the markets the scope of liability. It also gives them the opportunity to move on. Plaintiffs may prefer global settlements because they have greater leverage than they would individually to negotiate a better deal overall, but they may also feel left behind or left out, especially as they lose the power to negotiate individually.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Do you expect to see criminal trials in these cases? And would they also be solved with a global settlement?<\/p>\n<p><strong><strong>LAHAV:<\/strong> <\/strong>I don\u2019t know if there will be criminal trials, but any criminal action would be completely separate from the global settlement we have been discussing. Any global settlement would only resolve civil claims against these companies.<\/p>\n<p><em>This interview was edited for clarity and condensed for space.<\/em><\/p>\n\n\n\n<\/div>\n\n\t\t","protected":false},"excerpt":{"rendered":"<p>Alexandra Lahav, a fellow at Harvard\u2019s Radcliffe Institute, explains how a global settlement could handle the more than 2,000 lawsuits filed against drug companies and distributors.<\/p>\n","protected":false},"author":131912115,"featured_media":290702,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"gz_ga_pageviews":12,"gz_ga_lastupdated":"2020-10-23 13:24","document_color_palette":"crimson","author":"Colleen Walsh","affiliation":"Harvard Staff Writer","_category_override":"","_yoast_wpseo_primary_category":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1378],"tags":[44633,44634,38067,28665],"gazette-formats":[],"series":[],"class_list":["post-290682","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nation-world","tag-alexandra-lahav","tag-global-settlement","tag-opioid-crisis","tag-radcliffe-institute-for-advanced-study"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.0 (Yoast SEO v27.1.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Radcliffe fellow discusses a sweeping settlement in opioids lawsuits &#8212; Harvard Gazette<\/title>\n<meta name=\"description\" content=\"Alexandra Lahav, a fellow at Harvard\u2019s Radcliffe Institute, explains how a global settlement could handle the more than 2,000 lawsuits filed against drug companies and distributors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Radcliffe fellow discusses a sweeping settlement in opioids lawsuits\" \/>\n<meta property=\"og:description\" content=\"Alexandra Lahav, a fellow at Harvard\u2019s Radcliffe Institute, explains how a global settlement could handle the more than 2,000 lawsuits filed against drug companies and distributors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/\" \/>\n<meta property=\"og:site_name\" content=\"Harvard Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-07T19:59:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-09T01:28:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lian Parsons\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Radcliffe fellow discusses a sweeping settlement in opioids lawsuits\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/\"},\"author\":{\"name\":\"Lian Parsons\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/eb0a6f335aa1df1db33a426d73586ba4\"},\"headline\":\"Brokering an opioid settlement\",\"datePublished\":\"2019-11-07T19:59:07+00:00\",\"dateModified\":\"2023-11-09T01:28:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/\"},\"wordCount\":1422,\"publisher\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\",\"keywords\":[\"Alexandra Lahav\",\"global settlement\",\"Opioid crisis\",\"Radcliffe Institute for Advanced Study\"],\"articleSection\":[\"Nation &amp; World\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2019\",\"copyrightHolder\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/\",\"name\":\"Radcliffe fellow discusses a sweeping settlement in opioids lawsuits &#8212; Harvard Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\",\"datePublished\":\"2019-11-07T19:59:07+00:00\",\"dateModified\":\"2023-11-09T01:28:42+00:00\",\"description\":\"Alexandra Lahav, a fellow at Harvard\u2019s Radcliffe Institute, explains how a global settlement could handle the more than 2,000 lawsuits filed against drug companies and distributors.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#primaryimage\",\"url\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\",\"contentUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\",\"width\":2500,\"height\":1667,\"caption\":\"Pills laid out on a table.\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#website\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/\",\"name\":\"Harvard Gazette\",\"description\":\"Official news from Harvard University covering innovation in teaching, learning, and research\",\"publisher\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/news.harvard.edu\/gazette\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#organization\",\"name\":\"The Harvard Gazette\",\"url\":\"https:\/\/news.harvard.edu\/gazette\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg\",\"contentUrl\":\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg\",\"width\":164,\"height\":64,\"caption\":\"The Harvard Gazette\"},\"image\":{\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/eb0a6f335aa1df1db33a426d73586ba4\",\"name\":\"Lian Parsons\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Radcliffe fellow discusses a sweeping settlement in opioids lawsuits &#8212; Harvard Gazette","description":"Alexandra Lahav, a fellow at Harvard\u2019s Radcliffe Institute, explains how a global settlement could handle the more than 2,000 lawsuits filed against drug companies and distributors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/","og_locale":"en_US","og_type":"article","og_title":"Radcliffe fellow discusses a sweeping settlement in opioids lawsuits","og_description":"Alexandra Lahav, a fellow at Harvard\u2019s Radcliffe Institute, explains how a global settlement could handle the more than 2,000 lawsuits filed against drug companies and distributors.","og_url":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/","og_site_name":"Harvard Gazette","article_published_time":"2019-11-07T19:59:07+00:00","article_modified_time":"2023-11-09T01:28:42+00:00","og_image":[{"width":2500,"height":1667,"url":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg","type":"image\/jpeg"}],"author":"Lian Parsons","twitter_card":"summary_large_image","twitter_title":"Radcliffe fellow discusses a sweeping settlement in opioids lawsuits","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#article","isPartOf":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/"},"author":{"name":"Lian Parsons","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/eb0a6f335aa1df1db33a426d73586ba4"},"headline":"Brokering an opioid settlement","datePublished":"2019-11-07T19:59:07+00:00","dateModified":"2023-11-09T01:28:42+00:00","mainEntityOfPage":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/"},"wordCount":1422,"publisher":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#primaryimage"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg","keywords":["Alexandra Lahav","global settlement","Opioid crisis","Radcliffe Institute for Advanced Study"],"articleSection":["Nation &amp; World"],"inLanguage":"en-US","copyrightYear":"2019","copyrightHolder":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"}},{"@type":"WebPage","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/","url":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/","name":"Radcliffe fellow discusses a sweeping settlement in opioids lawsuits &#8212; Harvard Gazette","isPartOf":{"@id":"https:\/\/news.harvard.edu\/gazette\/#website"},"primaryImageOfPage":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#primaryimage"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#primaryimage"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg","datePublished":"2019-11-07T19:59:07+00:00","dateModified":"2023-11-09T01:28:42+00:00","description":"Alexandra Lahav, a fellow at Harvard\u2019s Radcliffe Institute, explains how a global settlement could handle the more than 2,000 lawsuits filed against drug companies and distributors.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/#primaryimage","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg","contentUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg","width":2500,"height":1667,"caption":"Pills laid out on a table."},{"@type":"WebSite","@id":"https:\/\/news.harvard.edu\/gazette\/#website","url":"https:\/\/news.harvard.edu\/gazette\/","name":"Harvard Gazette","description":"Official news from Harvard University covering innovation in teaching, learning, and research","publisher":{"@id":"https:\/\/news.harvard.edu\/gazette\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/news.harvard.edu\/gazette\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/news.harvard.edu\/gazette\/#organization","name":"The Harvard Gazette","url":"https:\/\/news.harvard.edu\/gazette\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg","contentUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg","width":164,"height":64,"caption":"The Harvard Gazette"},"image":{"@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/news.harvard.edu\/gazette\/#\/schema\/person\/eb0a6f335aa1df1db33a426d73586ba4","name":"Lian Parsons"}]}},"parsely":{"version":"1.1.0","canonical_url":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Brokering an opioid settlement","url":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/11\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\/"},"thumbnailUrl":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg?w=150","image":{"@type":"ImageObject","url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg"},"articleSection":"Nation &amp; World","author":[{"@type":"Person","name":"Lian Parsons"}],"creator":["Lian Parsons"],"publisher":{"@type":"Organization","name":"Harvard Gazette","logo":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2023\/12\/Harvard_Gazette_logo.svg"},"keywords":["alexandra lahav","global settlement","opioid crisis","radcliffe institute for advanced study"],"dateCreated":"2019-11-07T19:59:07Z","datePublished":"2019-11-07T19:59:07Z","dateModified":"2023-11-09T01:28:42Z"},"rendered":"<script type=\"application\/ld+json\" class=\"wp-parsely-metadata\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"Brokering an opioid settlement\",\"url\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/story\\\/2019\\\/11\\\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\\\/\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/story\\\/2019\\\/11\\\/radcliffe-fellow-discusses-a-sweeping-settlement-in-opioids-lawsuits\\\/\"},\"thumbnailUrl\":\"https:\\\/\\\/news.harvard.edu\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/stephen-foster-unsplash.jpg?w=150\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/news.harvard.edu\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/stephen-foster-unsplash.jpg\"},\"articleSection\":\"Nation &amp; World\",\"author\":[{\"@type\":\"Person\",\"name\":\"Lian Parsons\"}],\"creator\":[\"Lian Parsons\"],\"publisher\":{\"@type\":\"Organization\",\"name\":\"Harvard Gazette\",\"logo\":\"https:\\\/\\\/news.harvard.edu\\\/gazette\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Harvard_Gazette_logo.svg\"},\"keywords\":[\"alexandra lahav\",\"global settlement\",\"opioid crisis\",\"radcliffe institute for advanced study\"],\"dateCreated\":\"2019-11-07T19:59:07Z\",\"datePublished\":\"2019-11-07T19:59:07Z\",\"dateModified\":\"2023-11-09T01:28:42Z\"}<\/script>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/news.harvard.edu\/p.js"},"jetpack_featured_media_url":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg","has_blocks":true,"block_data":{"0":{"blockName":"harvard-gazette\/article-header","attrs":{"blockColorPalette":"","coloredHeading":"","creditText":"Stephen Foster\/Unsplash","displayDetails":"","displayTitle":"","categoryId":1378,"mediaAlt":"Pills laid out on a table.","mediaCaption":"","mediaId":290702,"mediaSize":"full","mediaType":"image","mediaUrl":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg","poster":"","title":"Brokering an opioid settlement","subheading":"Radcliffe fellow discusses prospects for a sweeping agreement in lawsuits","centeredImage":true,"className":"is-style-full-width-text-below","mediaHeight":1667,"mediaWidth":2500,"backgroundFixed":false,"backgroundTone":"light","coloredBackground":false,"displayOverlay":true,"fadeInText":false,"isAmbient":false,"mediaLength":"","mediaPosition":"","posterText":"","titleAbove":false,"useUncroppedImage":false,"lock":[],"metadata":[]},"innerBlocks":[],"innerHTML":"<figure class=\"wp-block-image\"><img alt=\"Pills laid out on a table.\" height=\"1667\" loading=\"eager\" src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\" width=\"2500\"\/><figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--credit\">Stephen Foster\/Unsplash<\/p><\/figcaption><\/figure>\n","innerContent":["<figure class=\"wp-block-image\"><img alt=\"Pills laid out on a table.\" height=\"1667\" loading=\"eager\" src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\" width=\"2500\"\/><figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--credit\">Stephen Foster\/Unsplash<\/p><\/figcaption><\/figure>\n"],"rendered":"<header\n\tclass=\"wp-block-harvard-gazette-article-header alignfull article-header is-style-full-width-text-below centered-image\"\n\tstyle=\" \"\n>\n\t<figure class=\"wp-block-image\"><img alt=\"Pills laid out on a table.\" height=\"1667\" loading=\"eager\" src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/stephen-foster-unsplash.jpg\" width=\"2500\"\/><figcaption class=\"wp-element-caption\"><p class=\"wp-element-caption--credit\">Stephen Foster\/Unsplash<\/p><\/figcaption><\/figure>\n\n\t<div class=\"article-header__content\">\n\t\t\t<a\n\t\t\tclass=\"article-header__category\"\n\t\t\thref=\"https:\/\/news.harvard.edu\/gazette\/section\/nation-world\/\"\n\t\t>\n\t\t\tNation &amp; World\t\t<\/a>\n\t\t\n\t\t<h1 class=\"article-header__title wp-block-heading \">\n\t\tBrokering an opioid settlement\t<\/h1>\n\n\t\n\t\t\t<\/div>\n\t\t\n\t<div class=\"article-header__meta\">\n\t\t<div class=\"wp-block-post-author\">\n\t\t\t<address class=\"wp-block-post-author__content\">\n\t\t\t\t\t<p class=\"author wp-block-post-author__name\">\n\t\tColleen Walsh\t<\/p>\n\t\t\t<p class=\"wp-block-post-author__byline\">\n\t\t\tHarvard Staff Writer\t\t<\/p>\n\t\t\t\t\t<\/address>\n\t\t<\/div>\n\n\t\t<time class=\"article-header__date\" datetime=\"2019-11-07\">\n\t\t\tNovember 7, 2019\t\t<\/time>\n\n\t\t<span class=\"article-header__reading-time\">\n\t\t\t8 min read\t\t<\/span>\n\t<\/div>\n\n\t\n\t\t\t<h2 class=\"article-header__subheading wp-block-heading\">\n\t\t\tRadcliffe fellow discusses prospects for a sweeping agreement in lawsuits\t\t<\/h2>\n\t\t\n<\/header>\n"},"2":{"blockName":"core\/group","attrs":{"templateLock":false,"metadata":{"name":"Article content"},"align":"wide","layout":{"type":"constrained","justifyContent":"center"},"tagName":"div","lock":[],"className":"","style":[],"backgroundColor":"","textColor":"","gradient":"","fontSize":"","fontFamily":"","borderColor":"","ariaLabel":"","anchor":""},"innerBlocks":[{"blockName":"core\/freeform","attrs":{"content":"","lock":[],"metadata":[]},"innerBlocks":[],"innerHTML":"\n\t\t<p>Drug companies and distributors are facing thousands of lawsuits filed by U.S. cities, towns, and tribal governments whose communities have been ravaged by the opioid epidemic, which has claimed hundreds of thousands of lives from overdoses. Resolving all those legal actions separately is impractical, many legal experts say. Instead, lawyers for the states and attorneys general are exploring a solution that would resolve all the cases in a so-called \u201cglobal deal.\u201d Currently two drug companies and three distributors have proposed a settlement framework for such a deal worth approximately $48 billion that would include cash and medication to treat addiction. But many local governments are wary of such an arrangement, skeptical about how the money would be divided. The Gazette spoke with <a href=\"https:\/\/www.radcliffe.harvard.edu\/people\/alexandra-d-lahav\">Alexandra Lahav,<\/a> 2019-20 Matina S. Horner Distinguished Visiting Professor at Harvard\u2019s <a href=\"https:\/\/www.radcliffe.harvard.edu\/\">Radcliffe Institute for Advanced Study, <\/a>and professor at the University of Connecticut who studies tort law, about how global settlements operate.<\/p>\n<h2 class=\"wp-block-heading\">Q&amp;A<\/h2>\n<h3 class=\"wp-block-heading\">Alexandra Lahav<\/h3>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is a global settlement? Do all parties involved have to sign on or agree to it?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> A global settlement is an agreement that includes everyone involved in a large-scale litigation. An example is the class action. In a class action, all the people who meet a certain description \u2014 for example, cellphone customers during a certain period \u2014 are included in the class. They are represented by a named plaintiff, and if that lawsuit reaches a settlement they would all be bound by it and not be able to sue on their own. But there are other ways to reach a global settlement as well. For example, a defendant can offer a single amount in settlement on condition that everyone who has a claim against them agrees to be part of that settlement. What makes a settlement global is that everyone or nearly everyone agrees to sign on.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>Can you talk a bit about the discussions around crafting an agreement to settle the thousands of opioids lawsuits?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>Right now, several attorneys general have suggested a global settlement in the opioids litigation. In that case, there is a very novel settlement structure on the table. The court has certified a class action, which includes all the cities and towns in the United States. They have the option to opt out of this class. If they don\u2019t, then they are deemed to have agreed to the following structure: When a settlement is reached, the terms will be circulated to the class. If 75 percent approve of the settlement, it will bind everyone, even the 25 percent who did not approve. This is called a \u201cnegotiated class action,\u201d and it has never been tried before. It was the idea of a Harvard law professor, William Rubenstein, and a Duke law professor, Francis McGovern.<\/p>\n","innerContent":["\n\t\t<p>Drug companies and distributors are facing thousands of lawsuits filed by U.S. cities, towns, and tribal governments whose communities have been ravaged by the opioid epidemic, which has claimed hundreds of thousands of lives from overdoses. Resolving all those legal actions separately is impractical, many legal experts say. Instead, lawyers for the states and attorneys general are exploring a solution that would resolve all the cases in a so-called \u201cglobal deal.\u201d Currently two drug companies and three distributors have proposed a settlement framework for such a deal worth approximately $48 billion that would include cash and medication to treat addiction. But many local governments are wary of such an arrangement, skeptical about how the money would be divided. The Gazette spoke with <a href=\"https:\/\/www.radcliffe.harvard.edu\/people\/alexandra-d-lahav\">Alexandra Lahav,<\/a> 2019-20 Matina S. Horner Distinguished Visiting Professor at Harvard\u2019s <a href=\"https:\/\/www.radcliffe.harvard.edu\/\">Radcliffe Institute for Advanced Study, <\/a>and professor at the University of Connecticut who studies tort law, about how global settlements operate.<\/p>\n<h2 class=\"wp-block-heading\">Q&amp;A<\/h2>\n<h3 class=\"wp-block-heading\">Alexandra Lahav<\/h3>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is a global settlement? Do all parties involved have to sign on or agree to it?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> A global settlement is an agreement that includes everyone involved in a large-scale litigation. An example is the class action. In a class action, all the people who meet a certain description \u2014 for example, cellphone customers during a certain period \u2014 are included in the class. They are represented by a named plaintiff, and if that lawsuit reaches a settlement they would all be bound by it and not be able to sue on their own. But there are other ways to reach a global settlement as well. For example, a defendant can offer a single amount in settlement on condition that everyone who has a claim against them agrees to be part of that settlement. What makes a settlement global is that everyone or nearly everyone agrees to sign on.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>Can you talk a bit about the discussions around crafting an agreement to settle the thousands of opioids lawsuits?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>Right now, several attorneys general have suggested a global settlement in the opioids litigation. In that case, there is a very novel settlement structure on the table. The court has certified a class action, which includes all the cities and towns in the United States. They have the option to opt out of this class. If they don\u2019t, then they are deemed to have agreed to the following structure: When a settlement is reached, the terms will be circulated to the class. If 75 percent approve of the settlement, it will bind everyone, even the 25 percent who did not approve. This is called a \u201cnegotiated class action,\u201d and it has never been tried before. It was the idea of a Harvard law professor, William Rubenstein, and a Duke law professor, Francis McGovern.<\/p>\n"],"rendered":"\n\t\t<p>Drug companies and distributors are facing thousands of lawsuits filed by U.S. cities, towns, and tribal governments whose communities have been ravaged by the opioid epidemic, which has claimed hundreds of thousands of lives from overdoses. Resolving all those legal actions separately is impractical, many legal experts say. Instead, lawyers for the states and attorneys general are exploring a solution that would resolve all the cases in a so-called \u201cglobal deal.\u201d Currently two drug companies and three distributors have proposed a settlement framework for such a deal worth approximately $48 billion that would include cash and medication to treat addiction. But many local governments are wary of such an arrangement, skeptical about how the money would be divided. The Gazette spoke with <a href=\"https:\/\/www.radcliffe.harvard.edu\/people\/alexandra-d-lahav\">Alexandra Lahav,<\/a> 2019-20 Matina S. Horner Distinguished Visiting Professor at Harvard\u2019s <a href=\"https:\/\/www.radcliffe.harvard.edu\/\">Radcliffe Institute for Advanced Study, <\/a>and professor at the University of Connecticut who studies tort law, about how global settlements operate.<\/p>\n<h2 class=\"wp-block-heading\">Q&amp;A<\/h2>\n<h3 class=\"wp-block-heading\">Alexandra Lahav<\/h3>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is a global settlement? Do all parties involved have to sign on or agree to it?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> A global settlement is an agreement that includes everyone involved in a large-scale litigation. An example is the class action. In a class action, all the people who meet a certain description \u2014 for example, cellphone customers during a certain period \u2014 are included in the class. They are represented by a named plaintiff, and if that lawsuit reaches a settlement they would all be bound by it and not be able to sue on their own. But there are other ways to reach a global settlement as well. For example, a defendant can offer a single amount in settlement on condition that everyone who has a claim against them agrees to be part of that settlement. What makes a settlement global is that everyone or nearly everyone agrees to sign on.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>Can you talk a bit about the discussions around crafting an agreement to settle the thousands of opioids lawsuits?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>Right now, several attorneys general have suggested a global settlement in the opioids litigation. In that case, there is a very novel settlement structure on the table. The court has certified a class action, which includes all the cities and towns in the United States. They have the option to opt out of this class. If they don\u2019t, then they are deemed to have agreed to the following structure: When a settlement is reached, the terms will be circulated to the class. If 75 percent approve of the settlement, it will bind everyone, even the 25 percent who did not approve. This is called a \u201cnegotiated class action,\u201d and it has never been tried before. It was the idea of a Harvard law professor, William Rubenstein, and a Duke law professor, Francis McGovern.<\/p>\n"},{"blockName":"core\/image","attrs":{"sizeSlug":"full","align":"right","id":290705,"caption":"\"It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on,\" said Alexandra Lahav. Photo by Tony Rinaldo","blob":"","url":"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg","alt":"Alexandra Lahav, Radcliffe fellow.","lightbox":[],"title":"","href":"","rel":"","linkClass":"","width":"","height":"","aspectRatio":"","scale":"","linkDestination":"","linkTarget":"","lock":[],"metadata":[],"className":"","style":[],"borderColor":"","anchor":""},"innerBlocks":[],"innerHTML":"\n\n\t<figure class=\"wp-block-image alignright  size-full is-resized\"><img src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg\" alt=\"Alexandra Lahav, Radcliffe fellow.\" class=\"wp-image-290705\"><figcaption class=\"wp-element-caption\">&quot;It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on,&quot; said Alexandra Lahav. Photo by Tony Rinaldo\t\t\t<\/figcaption><\/figure>\n\t","innerContent":["\n\n\t<figure class=\"wp-block-image alignright  size-full is-resized\"><img src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg\" alt=\"Alexandra Lahav, Radcliffe fellow.\" class=\"wp-image-290705\"><figcaption class=\"wp-element-caption\">&quot;It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on,&quot; said Alexandra Lahav. Photo by Tony Rinaldo\t\t\t<\/figcaption><\/figure>\n\t"],"rendered":"\n\n\t<figure class=\"wp-block-image alignright  size-full is-resized\"><img src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg\" alt=\"Alexandra Lahav, Radcliffe fellow.\" class=\"wp-image-290705\"><figcaption class=\"wp-element-caption\">&quot;It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on,&quot; said Alexandra Lahav. Photo by Tony Rinaldo\t\t\t<\/figcaption><\/figure>\n\t"},{"blockName":"core\/freeform","attrs":{"content":"","lock":[],"metadata":[]},"innerBlocks":[],"innerHTML":"\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is the challenge with this type of arrangement?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>There are a few. First, will everyone agree to join this settlement structure, knowing that they will be bound by a supermajority vote? Second, what about the attorneys general who have brought separate lawsuits, many of whom have opposed this settlement structure? Also what is the relationship between the state attorney general that represents the state as a whole, and all of the state\u2019s subdivisions? For example, let\u2019s say all the cities and towns in Massachusetts are included in a settlement. What then is the role of Attorney General Maura Healey? Is the whole greater than the sum of its parts? I haven\u2019t heard of anybody who knows the answer to this. It\u2019s sort of a local government question in a way. And each state law is going to be different with respect to the power of cities and towns to sue when the state is also suing.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What\u2019s the advantage of settling the lawsuits in this way?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>It\u2019s not realistic that every case is going to go to trial. We are talking about many thousands of cases, and the system just can\u2019t handle it. You can imagine a world where the judge holds a trial every six months, and the defendant settles one for $200 million here and another for $200 million there, and this goes on and on and on. That's just not good for the communities, and it\u2019s not good for the defendants. The idea behind a global settlement is to come up with something that benefits both and that resolves the dispute.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> How would a global settlement like this compare to the Big Tobacco case in 1998?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> There are some similarities, in that both are public health crises that led to massive lawsuits. But there are also a few important differences. First, the tobacco cases were settled exclusively by state attorneys general. Here both attorneys general and individual municipalities are suing, and they have more competing interests. This makes it harder to reach a global agreement. Second, there appears to be less money available here than there was in the tobacco case, which settled for around $200 billion.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> Do you think public anger and the desire for an admission of guilt or an apology factor into whether or not these cases end in a settlement, or are taken to trial?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on. Others have played a relatively small role in the opioid crisis. That said, I do think people want accountability. But you know, one of the things about the American system that\u2019s so interesting is that we do settle a lot of cases, and in most of those settlements, there is no apology, and there is no admission of liability. Instead, we sort of take the amount of money as the apology and the admission of liability, as if the dollars speak for the accountability.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What can be put in place in these settlements to stop similar crises from happening?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> This is a very difficult question to answer. The general theory of deterrence says that if wrongdoers are forced to pay for the harms they cause, then in the future companies considering wrongdoing will not do similar things. We hope that is the case. But it isn\u2019t clear that a litigation can prevent the kind of regulatory failure that we saw in the opioids situation. If there is a settlement it\u2019s likely to provide some relief to states and localities that are suffering, but it is not clear what preventative effect it will have.<\/p>\n","innerContent":["\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is the challenge with this type of arrangement?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>There are a few. First, will everyone agree to join this settlement structure, knowing that they will be bound by a supermajority vote? Second, what about the attorneys general who have brought separate lawsuits, many of whom have opposed this settlement structure? Also what is the relationship between the state attorney general that represents the state as a whole, and all of the state\u2019s subdivisions? For example, let\u2019s say all the cities and towns in Massachusetts are included in a settlement. What then is the role of Attorney General Maura Healey? Is the whole greater than the sum of its parts? I haven\u2019t heard of anybody who knows the answer to this. It\u2019s sort of a local government question in a way. And each state law is going to be different with respect to the power of cities and towns to sue when the state is also suing.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What\u2019s the advantage of settling the lawsuits in this way?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>It\u2019s not realistic that every case is going to go to trial. We are talking about many thousands of cases, and the system just can\u2019t handle it. You can imagine a world where the judge holds a trial every six months, and the defendant settles one for $200 million here and another for $200 million there, and this goes on and on and on. That's just not good for the communities, and it\u2019s not good for the defendants. The idea behind a global settlement is to come up with something that benefits both and that resolves the dispute.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> How would a global settlement like this compare to the Big Tobacco case in 1998?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> There are some similarities, in that both are public health crises that led to massive lawsuits. But there are also a few important differences. First, the tobacco cases were settled exclusively by state attorneys general. Here both attorneys general and individual municipalities are suing, and they have more competing interests. This makes it harder to reach a global agreement. Second, there appears to be less money available here than there was in the tobacco case, which settled for around $200 billion.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> Do you think public anger and the desire for an admission of guilt or an apology factor into whether or not these cases end in a settlement, or are taken to trial?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on. Others have played a relatively small role in the opioid crisis. That said, I do think people want accountability. But you know, one of the things about the American system that\u2019s so interesting is that we do settle a lot of cases, and in most of those settlements, there is no apology, and there is no admission of liability. Instead, we sort of take the amount of money as the apology and the admission of liability, as if the dollars speak for the accountability.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What can be put in place in these settlements to stop similar crises from happening?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> This is a very difficult question to answer. The general theory of deterrence says that if wrongdoers are forced to pay for the harms they cause, then in the future companies considering wrongdoing will not do similar things. We hope that is the case. But it isn\u2019t clear that a litigation can prevent the kind of regulatory failure that we saw in the opioids situation. If there is a settlement it\u2019s likely to provide some relief to states and localities that are suffering, but it is not clear what preventative effect it will have.<\/p>\n"],"rendered":"\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is the challenge with this type of arrangement?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>There are a few. First, will everyone agree to join this settlement structure, knowing that they will be bound by a supermajority vote? Second, what about the attorneys general who have brought separate lawsuits, many of whom have opposed this settlement structure? Also what is the relationship between the state attorney general that represents the state as a whole, and all of the state\u2019s subdivisions? For example, let\u2019s say all the cities and towns in Massachusetts are included in a settlement. What then is the role of Attorney General Maura Healey? Is the whole greater than the sum of its parts? I haven\u2019t heard of anybody who knows the answer to this. It\u2019s sort of a local government question in a way. And each state law is going to be different with respect to the power of cities and towns to sue when the state is also suing.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What\u2019s the advantage of settling the lawsuits in this way?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>It\u2019s not realistic that every case is going to go to trial. We are talking about many thousands of cases, and the system just can\u2019t handle it. You can imagine a world where the judge holds a trial every six months, and the defendant settles one for $200 million here and another for $200 million there, and this goes on and on and on. That's just not good for the communities, and it\u2019s not good for the defendants. The idea behind a global settlement is to come up with something that benefits both and that resolves the dispute.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> How would a global settlement like this compare to the Big Tobacco case in 1998?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> There are some similarities, in that both are public health crises that led to massive lawsuits. But there are also a few important differences. First, the tobacco cases were settled exclusively by state attorneys general. Here both attorneys general and individual municipalities are suing, and they have more competing interests. This makes it harder to reach a global agreement. Second, there appears to be less money available here than there was in the tobacco case, which settled for around $200 billion.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> Do you think public anger and the desire for an admission of guilt or an apology factor into whether or not these cases end in a settlement, or are taken to trial?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on. Others have played a relatively small role in the opioid crisis. That said, I do think people want accountability. But you know, one of the things about the American system that\u2019s so interesting is that we do settle a lot of cases, and in most of those settlements, there is no apology, and there is no admission of liability. Instead, we sort of take the amount of money as the apology and the admission of liability, as if the dollars speak for the accountability.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What can be put in place in these settlements to stop similar crises from happening?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> This is a very difficult question to answer. The general theory of deterrence says that if wrongdoers are forced to pay for the harms they cause, then in the future companies considering wrongdoing will not do similar things. We hope that is the case. But it isn\u2019t clear that a litigation can prevent the kind of regulatory failure that we saw in the opioids situation. If there is a settlement it\u2019s likely to provide some relief to states and localities that are suffering, but it is not clear what preventative effect it will have.<\/p>\n"},{"blockName":"harvard-gazette\/supporting-content","attrs":{"id":"11de4a1e-1353-4dd2-8ead-51f99878bad3","align":"left","allowedBlocks":[],"style":[],"lock":[],"metadata":[],"className":""},"innerBlocks":[{"blockName":"harvard-gazette\/featured-articles","attrs":{"autoGenerate":false,"className":"is-style-grid-list","inPostContent":true,"numberOfPosts":4,"postIds":[288948,274962,267671,260515],"showExcerpt":false,"title":"More like this","category":"","carouselOnDesktop":false,"isEditor":false,"linkText":"See all book reviews","passPostIds":false,"postOverrides":[],"postTypeOverride":"post","receivePostIds":false,"series":"","showCategory":true,"showDate":true,"gridColumns":2,"showDropShadow":false,"showFormat":true,"showImage":true,"showImageZoom":false,"showSeries":true,"showReadMore":true,"showReadTime":true,"tags":[],"useCurrentTerm":false,"lock":[],"metadata":[],"align":"","style":[]},"innerBlocks":[],"innerHTML":"","innerContent":[],"rendered":"\n\t<div class=\"featured-articles is-post-type-post is-style-grid-list\"  style=\"\">\n\t\t\t\t\t\t<h2 class=\"featured-articles__title wp-block-heading\">More like this<\/h2>\n\t\t\t\t<ul class=\"featured-articles__list \">\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"Raina McMahan and Dr. Sarah Wakeman at the confernce\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/10\/stigma-of-opioids-keeps-users-from-seeking-help-taints-views-of-medical-professionals\/\">Stigma of opioids a hurdle to solving crisis<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-10-11\">\n\t\t\t\t\t\t\tOctober 11, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t6 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"Pills spilling from a bottle\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/05\/harvard-michigan-opioid-summit-explores-addiction-policy\/\">Pharma-to-doc marketing a vulnerability in opioid fight<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-05-13\">\n\t\t\t\t\t\t\tMay 13, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t6 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"assortment of pills\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/03\/dramatic-shifts-in-first-time-opioid-prescriptions-bring-hope-concern\/\">First-time opioid prescriptions drop by 50 percent<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-03-13\">\n\t\t\t\t\t\t\tMarch 13, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t4 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"A fentanyl user holds a needle.\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2018\/12\/harvard-psychologist-discusses-decline-in-u-s-life-expectancy\/\">A nation nearer to the grave<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2018-12-10\">\n\t\t\t\t\t\t\tDecember 10, 2018\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\tlong read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\t\t<\/ul>\n\t\t\t<\/div>\n\n\t"}],"innerHTML":"<div class=\"wp-block-harvard-gazette-supporting-content alignleft supporting-content\" id=\"supporting-content-11de4a1e-1353-4dd2-8ead-51f99878bad3\"><\/div>","innerContent":["<div class=\"wp-block-harvard-gazette-supporting-content alignleft supporting-content\" id=\"supporting-content-11de4a1e-1353-4dd2-8ead-51f99878bad3\">","<\/div>"],"rendered":"<div class=\"wp-block-harvard-gazette-supporting-content alignleft supporting-content\" id=\"supporting-content-11de4a1e-1353-4dd2-8ead-51f99878bad3\">\n\t<div class=\"featured-articles is-post-type-post is-style-grid-list\"  style=\"\">\n\t\t\t\t\t\t<h2 class=\"featured-articles__title wp-block-heading\">More like this<\/h2>\n\t\t\t\t<ul class=\"featured-articles__list \">\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"Raina McMahan and Dr. Sarah Wakeman at the confernce\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/10\/stigma-of-opioids-keeps-users-from-seeking-help-taints-views-of-medical-professionals\/\">Stigma of opioids a hurdle to solving crisis<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-10-11\">\n\t\t\t\t\t\t\tOctober 11, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t6 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"Pills spilling from a bottle\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/05\/harvard-michigan-opioid-summit-explores-addiction-policy\/\">Pharma-to-doc marketing a vulnerability in opioid fight<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-05-13\">\n\t\t\t\t\t\t\tMay 13, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t6 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"assortment of pills\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/03\/dramatic-shifts-in-first-time-opioid-prescriptions-bring-hope-concern\/\">First-time opioid prescriptions drop by 50 percent<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-03-13\">\n\t\t\t\t\t\t\tMarch 13, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t4 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"A fentanyl user holds a needle.\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2018\/12\/harvard-psychologist-discusses-decline-in-u-s-life-expectancy\/\">A nation nearer to the grave<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2018-12-10\">\n\t\t\t\t\t\t\tDecember 10, 2018\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\tlong read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\t\t<\/ul>\n\t\t\t<\/div>\n\n\t<\/div>"},{"blockName":"core\/freeform","attrs":{"content":"","lock":[],"metadata":[]},"innerBlocks":[],"innerHTML":"\r\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What do you expect to happen next and what are the chances that the global settlement under consideration will be achieved?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Right now there is a settlement proposal on the table proposed by several attorneys general for $48 billion over a period of years. But it is not clear that it will be agreed to by the lawyers for the local governments, who at the moment are opposing it. And some states have also voiced concerns. In order to reach a global settlement, that proposal would need the agreement of the lawyers representing this class of localities. I think we will see a settlement eventually, but when and for how much remains to be seen.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Are there specific reasons why plaintiffs like or prefer a global settlement, and why defendants prefer it?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Defendants prefer a global settlement because they can wrap up their liability at once. This allows them to announce to the markets the scope of liability. It also gives them the opportunity to move on. Plaintiffs may prefer global settlements because they have greater leverage than they would individually to negotiate a better deal overall, but they may also feel left behind or left out, especially as they lose the power to negotiate individually.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Do you expect to see criminal trials in these cases? And would they also be solved with a global settlement?<\/p>\n<p><strong><strong>LAHAV:<\/strong> <\/strong>I don\u2019t know if there will be criminal trials, but any criminal action would be completely separate from the global settlement we have been discussing. Any global settlement would only resolve civil claims against these companies.<\/p>\n<p><em>This interview was edited for clarity and condensed for space.<\/em><\/p>\n\n","innerContent":["\r\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What do you expect to happen next and what are the chances that the global settlement under consideration will be achieved?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Right now there is a settlement proposal on the table proposed by several attorneys general for $48 billion over a period of years. But it is not clear that it will be agreed to by the lawyers for the local governments, who at the moment are opposing it. And some states have also voiced concerns. In order to reach a global settlement, that proposal would need the agreement of the lawyers representing this class of localities. I think we will see a settlement eventually, but when and for how much remains to be seen.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Are there specific reasons why plaintiffs like or prefer a global settlement, and why defendants prefer it?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Defendants prefer a global settlement because they can wrap up their liability at once. This allows them to announce to the markets the scope of liability. It also gives them the opportunity to move on. Plaintiffs may prefer global settlements because they have greater leverage than they would individually to negotiate a better deal overall, but they may also feel left behind or left out, especially as they lose the power to negotiate individually.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Do you expect to see criminal trials in these cases? And would they also be solved with a global settlement?<\/p>\n<p><strong><strong>LAHAV:<\/strong> <\/strong>I don\u2019t know if there will be criminal trials, but any criminal action would be completely separate from the global settlement we have been discussing. Any global settlement would only resolve civil claims against these companies.<\/p>\n<p><em>This interview was edited for clarity and condensed for space.<\/em><\/p>\n\n"],"rendered":"\r\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What do you expect to happen next and what are the chances that the global settlement under consideration will be achieved?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Right now there is a settlement proposal on the table proposed by several attorneys general for $48 billion over a period of years. But it is not clear that it will be agreed to by the lawyers for the local governments, who at the moment are opposing it. And some states have also voiced concerns. In order to reach a global settlement, that proposal would need the agreement of the lawyers representing this class of localities. I think we will see a settlement eventually, but when and for how much remains to be seen.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Are there specific reasons why plaintiffs like or prefer a global settlement, and why defendants prefer it?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Defendants prefer a global settlement because they can wrap up their liability at once. This allows them to announce to the markets the scope of liability. It also gives them the opportunity to move on. Plaintiffs may prefer global settlements because they have greater leverage than they would individually to negotiate a better deal overall, but they may also feel left behind or left out, especially as they lose the power to negotiate individually.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Do you expect to see criminal trials in these cases? And would they also be solved with a global settlement?<\/p>\n<p><strong><strong>LAHAV:<\/strong> <\/strong>I don\u2019t know if there will be criminal trials, but any criminal action would be completely separate from the global settlement we have been discussing. Any global settlement would only resolve civil claims against these companies.<\/p>\n<p><em>This interview was edited for clarity and condensed for space.<\/em><\/p>\n\n"}],"innerHTML":"\n<div class=\"wp-block-group alignwide\">\n\n\r\n\t\n\t\r\n\r\n\r\n\n\n<\/div>\n","innerContent":["\n<div class=\"wp-block-group alignwide\">\n\n","\r\n\t","\n\t\r\n","\r\n","\r\n","\n\n<\/div>\n"],"rendered":"\n<div class=\"wp-block-group alignwide has-global-padding is-content-justification-center is-layout-constrained wp-block-group-is-layout-constrained\">\n\n\n\t\t<p>Drug companies and distributors are facing thousands of lawsuits filed by U.S. cities, towns, and tribal governments whose communities have been ravaged by the opioid epidemic, which has claimed hundreds of thousands of lives from overdoses. Resolving all those legal actions separately is impractical, many legal experts say. Instead, lawyers for the states and attorneys general are exploring a solution that would resolve all the cases in a so-called \u201cglobal deal.\u201d Currently two drug companies and three distributors have proposed a settlement framework for such a deal worth approximately $48 billion that would include cash and medication to treat addiction. But many local governments are wary of such an arrangement, skeptical about how the money would be divided. The Gazette spoke with <a href=\"https:\/\/www.radcliffe.harvard.edu\/people\/alexandra-d-lahav\">Alexandra Lahav,<\/a> 2019-20 Matina S. Horner Distinguished Visiting Professor at Harvard\u2019s <a href=\"https:\/\/www.radcliffe.harvard.edu\/\">Radcliffe Institute for Advanced Study, <\/a>and professor at the University of Connecticut who studies tort law, about how global settlements operate.<\/p>\n<h2 class=\"wp-block-heading\">Q&amp;A<\/h2>\n<h3 class=\"wp-block-heading\">Alexandra Lahav<\/h3>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is a global settlement? Do all parties involved have to sign on or agree to it?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> A global settlement is an agreement that includes everyone involved in a large-scale litigation. An example is the class action. In a class action, all the people who meet a certain description \u2014 for example, cellphone customers during a certain period \u2014 are included in the class. They are represented by a named plaintiff, and if that lawsuit reaches a settlement they would all be bound by it and not be able to sue on their own. But there are other ways to reach a global settlement as well. For example, a defendant can offer a single amount in settlement on condition that everyone who has a claim against them agrees to be part of that settlement. What makes a settlement global is that everyone or nearly everyone agrees to sign on.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>Can you talk a bit about the discussions around crafting an agreement to settle the thousands of opioids lawsuits?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>Right now, several attorneys general have suggested a global settlement in the opioids litigation. In that case, there is a very novel settlement structure on the table. The court has certified a class action, which includes all the cities and towns in the United States. They have the option to opt out of this class. If they don\u2019t, then they are deemed to have agreed to the following structure: When a settlement is reached, the terms will be circulated to the class. If 75 percent approve of the settlement, it will bind everyone, even the 25 percent who did not approve. This is called a \u201cnegotiated class action,\u201d and it has never been tried before. It was the idea of a Harvard law professor, William Rubenstein, and a Duke law professor, Francis McGovern.<\/p>\n\r\n\t\n\n\t<figure class=\"wp-block-image alignright  size-full is-resized\"><img src=\"https:\/\/news.harvard.edu\/gazette\/wp-content\/uploads\/2019\/10\/Tony-Rinaldo-scaled.jpg\" alt=\"Alexandra Lahav, Radcliffe fellow.\" class=\"wp-image-290705\"><figcaption class=\"wp-element-caption\">&quot;It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on,&quot; said Alexandra Lahav. Photo by Tony Rinaldo\t\t\t<\/figcaption><\/figure>\n\t\n\t\r\n\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What is the challenge with this type of arrangement?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>There are a few. First, will everyone agree to join this settlement structure, knowing that they will be bound by a supermajority vote? Second, what about the attorneys general who have brought separate lawsuits, many of whom have opposed this settlement structure? Also what is the relationship between the state attorney general that represents the state as a whole, and all of the state\u2019s subdivisions? For example, let\u2019s say all the cities and towns in Massachusetts are included in a settlement. What then is the role of Attorney General Maura Healey? Is the whole greater than the sum of its parts? I haven\u2019t heard of anybody who knows the answer to this. It\u2019s sort of a local government question in a way. And each state law is going to be different with respect to the power of cities and towns to sue when the state is also suing.<\/p>\n<p><strong><strong>GAZETTE:<\/strong> <\/strong>What\u2019s the advantage of settling the lawsuits in this way?<\/p>\n<p><strong><strong>LAHAV:<\/strong>\u00a0<\/strong>It\u2019s not realistic that every case is going to go to trial. We are talking about many thousands of cases, and the system just can\u2019t handle it. You can imagine a world where the judge holds a trial every six months, and the defendant settles one for $200 million here and another for $200 million there, and this goes on and on and on. That's just not good for the communities, and it\u2019s not good for the defendants. The idea behind a global settlement is to come up with something that benefits both and that resolves the dispute.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> How would a global settlement like this compare to the Big Tobacco case in 1998?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> There are some similarities, in that both are public health crises that led to massive lawsuits. But there are also a few important differences. First, the tobacco cases were settled exclusively by state attorneys general. Here both attorneys general and individual municipalities are suing, and they have more competing interests. This makes it harder to reach a global agreement. Second, there appears to be less money available here than there was in the tobacco case, which settled for around $200 billion.<\/p>\n<p><strong><strong>GAZETTE:<\/strong><\/strong> Do you think public anger and the desire for an admission of guilt or an apology factor into whether or not these cases end in a settlement, or are taken to trial?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> It seems to me there isn\u2019t an appetite to have all of these companies go bankrupt. For example, some of them distribute a lot of drugs that people depend on. Others have played a relatively small role in the opioid crisis. That said, I do think people want accountability. But you know, one of the things about the American system that\u2019s so interesting is that we do settle a lot of cases, and in most of those settlements, there is no apology, and there is no admission of liability. Instead, we sort of take the amount of money as the apology and the admission of liability, as if the dollars speak for the accountability.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What can be put in place in these settlements to stop similar crises from happening?<\/p>\n<p><strong><strong>LAHAV:<\/strong><\/strong> This is a very difficult question to answer. The general theory of deterrence says that if wrongdoers are forced to pay for the harms they cause, then in the future companies considering wrongdoing will not do similar things. We hope that is the case. But it isn\u2019t clear that a litigation can prevent the kind of regulatory failure that we saw in the opioids situation. If there is a settlement it\u2019s likely to provide some relief to states and localities that are suffering, but it is not clear what preventative effect it will have.<\/p>\n\r\n<div class=\"wp-block-harvard-gazette-supporting-content alignleft supporting-content\" id=\"supporting-content-11de4a1e-1353-4dd2-8ead-51f99878bad3\">\n\t<div class=\"featured-articles is-post-type-post is-style-grid-list\"  style=\"\">\n\t\t\t\t\t\t<h2 class=\"featured-articles__title wp-block-heading\">More like this<\/h2>\n\t\t\t\t<ul class=\"featured-articles__list \">\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"Raina McMahan and Dr. Sarah Wakeman at the confernce\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/10\/Raina_HSPH_OpioidSummit_069.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/10\/stigma-of-opioids-keeps-users-from-seeking-help-taints-views-of-medical-professionals\/\">Stigma of opioids a hurdle to solving crisis<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-10-11\">\n\t\t\t\t\t\t\tOctober 11, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t6 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"Pills spilling from a bottle\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/05\/Opiod_iStock-92189516_2500.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/05\/harvard-michigan-opioid-summit-explores-addiction-policy\/\">Pharma-to-doc marketing a vulnerability in opioid fight<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-05-13\">\n\t\t\t\t\t\t\tMay 13, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t6 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"assortment of pills\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2019\/03\/dramatic-shifts-in-first-time-opioid-prescriptions-bring-hope-concern\/\">First-time opioid prescriptions drop by 50 percent<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2019-03-13\">\n\t\t\t\t\t\t\tMarch 13, 2019\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\t4 min read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\n\t\t<li class=\"featured-article \">\n\t\t\t\t\t\t<figure class=\"featured-article__image\">\n\t\t\t\t<img width=\"1200\" height=\"750\" src=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1200%2C750\" class=\"attachment-large-landscape-desktop size-large-landscape-desktop\" alt=\"A fentanyl user holds a needle.\" loading=\"lazy\" srcset=\"https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=608,380 608w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=784,490 784w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1024,640 1024w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1200,750 1200w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1488,930 1488w, https:\/\/news.harvard.edu\/wp-content\/uploads\/2018\/12\/AP_18312840056546.jpg?resize=1680,1050 1680w\" \/>\t\t\t\t\t\t\t<\/figure>\n\t\t\t\n\t\t\t<div class=\"featured-article__content\">\n\t\t\t\t\t\t<a class=\"featured-article__category\" href=\"https:\/\/news.harvard.edu\/gazette\/section\/health\/\">\n\t\t\tHealth\t\t<\/a>\n\t\t\n\t\t\t\t<h3 class=\"featured-article__title wp-block-heading \"><a href=\"https:\/\/news.harvard.edu\/gazette\/story\/2018\/12\/harvard-psychologist-discusses-decline-in-u-s-life-expectancy\/\">A nation nearer to the grave<\/a><\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t<div class=\"featured-article__meta\">\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<time class=\"featured-article__date\" datetime=\"2018-12-10\">\n\t\t\t\t\t\t\tDecember 10, 2018\t\t\t\t\t\t<\/time>\n\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"featured-article__reading-time\">\n\t\t\t\t\t\t\tlong read\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/li>\n\n\t\t\t\t<\/ul>\n\t\t\t<\/div>\n\n\t<\/div>\r\n\r\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>What do you expect to happen next and what are the chances that the global settlement under consideration will be achieved?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Right now there is a settlement proposal on the table proposed by several attorneys general for $48 billion over a period of years. But it is not clear that it will be agreed to by the lawyers for the local governments, who at the moment are opposing it. And some states have also voiced concerns. In order to reach a global settlement, that proposal would need the agreement of the lawyers representing this class of localities. I think we will see a settlement eventually, but when and for how much remains to be seen.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Are there specific reasons why plaintiffs like or prefer a global settlement, and why defendants prefer it?<\/p>\n<p><strong><strong>LAHAV:\u00a0<\/strong><\/strong>Defendants prefer a global settlement because they can wrap up their liability at once. This allows them to announce to the markets the scope of liability. It also gives them the opportunity to move on. Plaintiffs may prefer global settlements because they have greater leverage than they would individually to negotiate a better deal overall, but they may also feel left behind or left out, especially as they lose the power to negotiate individually.<\/p>\n<p><strong><strong>GAZETTE:\u00a0<\/strong><\/strong>Do you expect to see criminal trials in these cases? And would they also be solved with a global settlement?<\/p>\n<p><strong><strong>LAHAV:<\/strong> <\/strong>I don\u2019t know if there will be criminal trials, but any criminal action would be completely separate from the global settlement we have been discussing. Any global settlement would only resolve civil claims against these companies.<\/p>\n<p><em>This interview was edited for clarity and condensed for space.<\/em><\/p>\n\n\n\n<\/div>\n"}},"jetpack-related-posts":[{"id":329552,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2021\/08\/applying-lessons-learned-from-the-tobacco-settlement-to-opioid-negotiations\/","url_meta":{"origin":290682,"position":0},"title":"Learning the hard way","author":"Lian Parsons","date":"August 4, 2021","format":false,"excerpt":"Harvard\u2019s Allan M. Brandt, history of science scholar and \u201cCigarette Century\u201d author, says opioid negotiators should heed lessons from tobacco settlement.","rel":"","context":"In &quot;Nation &amp; World&quot;","block_context":{"text":"Nation &amp; World","link":"https:\/\/news.harvard.edu\/gazette\/section\/nation-world\/"},"img":{"alt_text":"Cigarette, tobacco and pills.","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2021\/08\/iStock-cigarettespills.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2021\/08\/iStock-cigarettespills.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2021\/08\/iStock-cigarettespills.jpg?resize=525%2C300 1.5x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2021\/08\/iStock-cigarettespills.jpg?resize=700%2C400 2x"},"classes":[]},{"id":232651,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2017\/10\/radcliffe-symposium-looks-at-epidemics-from-ebola-to-opioids\/","url_meta":{"origin":290682,"position":1},"title":"Understanding what plagues us","author":"gazettejohnbaglione","date":"October 31, 2017","format":false,"excerpt":"A Radcliffe Institute for Advanced Study symposium looked at epidemics and emerging ways to contain contagion, both biological and societal.","rel":"","context":"In &quot;Health&quot;","block_context":{"text":"Health","link":"https:\/\/news.harvard.edu\/gazette\/section\/health\/"},"img":{"alt_text":"","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2017\/10\/contagion_garratt.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2017\/10\/contagion_garratt.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2017\/10\/contagion_garratt.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":267671,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2019\/03\/dramatic-shifts-in-first-time-opioid-prescriptions-bring-hope-concern\/","url_meta":{"origin":290682,"position":2},"title":"First-time opioid prescriptions drop by 50 percent","author":"harvardgazette","date":"March 13, 2019","format":false,"excerpt":"Based on a Harvard study, the monthly rate of first-time opioid prescriptions dropped by more than half between 2012 and 2017. A new concern now is whether some patients are getting less-than-adequate treatment for their pain.","rel":"","context":"In &quot;Health&quot;","block_context":{"text":"Health","link":"https:\/\/news.harvard.edu\/gazette\/section\/health\/"},"img":{"alt_text":"assortment of pills","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=525%2C300 1.5x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2019\/03\/Opioids.jpg?resize=700%2C400 2x"},"classes":[]},{"id":344441,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2022\/06\/new-tool-models-evolution-of-opioid-crisis\/","url_meta":{"origin":290682,"position":3},"title":"New tool models evolution of opioid crisis","author":"harvardgazette","date":"June 3, 2022","format":false,"excerpt":"To help combat the opioid crisis, researchers have developed a tool, known as SOURCE, which taps national data on opioids to track stages of use and misuse, including use initiation, treatment, relapse, and death by overdose.","rel":"","context":"In &quot;Health&quot;","block_context":{"text":"Health","link":"https:\/\/news.harvard.edu\/gazette\/section\/health\/"},"img":{"alt_text":"Opioid pills and syringes.","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2022\/06\/iStock-opioids.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2022\/06\/iStock-opioids.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2022\/06\/iStock-opioids.jpg?resize=525%2C300 1.5x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2022\/06\/iStock-opioids.jpg?resize=700%2C400 2x"},"classes":[]},{"id":137642,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2013\/05\/radcliffe_fellows_2013-14\/","url_meta":{"origin":290682,"position":4},"title":"Radcliffe opens doors of discovery","author":"harvardgazette","date":"May 7, 2013","format":false,"excerpt":"The Radcliffe Institute for Advanced Study announced 49 artists and scholars who have been selected as its 2013-2014 fellows, among them are 15 Harvard faculty.","rel":"","context":"In &quot;Campus &amp; Community&quot;","block_context":{"text":"Campus &amp; Community","link":"https:\/\/news.harvard.edu\/gazette\/section\/campus-community\/"},"img":{"alt_text":"","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/05\/fy14-radcliffe-fellows_605.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/05\/fy14-radcliffe-fellows_605.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2013\/05\/fy14-radcliffe-fellows_605.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":222829,"url":"https:\/\/news.harvard.edu\/gazette\/story\/2017\/03\/clear-solutions-murky-path-forward-discussed-in-harvard-panel-on-opioid-crisis\/","url_meta":{"origin":290682,"position":5},"title":"Prescription crackdown called crucial in opioid fight","author":"gazettejohnbaglione","date":"March 31, 2017","format":false,"excerpt":"Former Vermont governor and others discussed possible strategies against the U.S. opioid epidemic in a conversation at the JFK Jr. Forum.","rel":"","context":"In &quot;Nation &amp; World&quot;","block_context":{"text":"Nation &amp; World","link":"https:\/\/news.harvard.edu\/gazette\/section\/nation-world\/"},"img":{"alt_text":"","src":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2017\/03\/032917_opiods_028_605.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/news.harvard.edu\/wp-content\/uploads\/2017\/03\/032917_opiods_028_605.jpg?resize=350%2C200 1x, https:\/\/news.harvard.edu\/wp-content\/uploads\/2017\/03\/032917_opiods_028_605.jpg?resize=525%2C300 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/290682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/users\/131912115"}],"replies":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/comments?post=290682"}],"version-history":[{"count":13,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/290682\/revisions"}],"predecessor-version":[{"id":291278,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/posts\/290682\/revisions\/291278"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/media\/290702"}],"wp:attachment":[{"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/media?parent=290682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/categories?post=290682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/tags?post=290682"},{"taxonomy":"format","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/gazette-formats?post=290682"},{"taxonomy":"series","embeddable":true,"href":"https:\/\/news.harvard.edu\/gazette\/wp-json\/wp\/v2\/series?post=290682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}